Canine Lymphoma Immunophenotyping: When Cell Lineage Changes the Conversation
Summary
A conservative guide to what cytology, histopathology, immunohistochemistry, flow cytometry, and clonality testing contribute when canine lymphoma is suspected.
Article
Educational medical disclaimer: This article provides general information and cannot diagnose lymphoma, select a test, predict an outcome, or replace care from a licensed veterinarian who has examined the dog.
Lymphoma is not one uniform disease. Even when enlarged lymph nodes and cytology make lymphoma likely, the cell lineage and microscopic pattern can influence how a veterinary team describes expected behavior, discusses treatment, and interprets later response. The practical goal of immunophenotyping is not to collect labels for their own sake. It is to answer a defined clinical question with a sample that can answer it.
Start with the level of certainty
A fine-needle aspirate of an affected node is often a useful first sample because it can show a population of abnormal lymphoid cells with relatively little burden for the dog. Cytology may strongly support lymphoma, but it does not preserve tissue architecture. Architecture matters when the team needs a full histologic classification, must distinguish an unusual reactive process from neoplasia, or expects the subtype to affect a major decision. The 2025 international consensus statement on canine nodal lymphoma describes histopathology combined with immunohistochemistry as the basis for complete classification, while recognizing cytology and other ancillary tests as valuable parts of a diagnostic pathway.
What immunophenotyping adds
Immunophenotyping identifies proteins associated with cell lineage. In practice, the central question is often whether the abnormal cells show a B-cell or T-cell phenotype, although classification can be more detailed. Immunohistochemistry applies markers to a tissue section, preserving architecture. Flow cytometry examines markers on individual cells in a fresh cell suspension and can return information quickly when an appropriate sample reaches the laboratory in usable condition. Published consensus recommendations emphasize standardized collection, analysis, and reporting because sample quality, marker panels, and gating choices can affect interpretation.
Neither method should be treated as a stand-alone prognosis machine. Lineage is one component of the case. Anatomic form, histologic subtype, stage, clinical signs, prior corticosteroid exposure, concurrent illness, and response over time may all matter. A population statistic cannot promise what will happen to an individual dog.
Where PARR fits
PCR for antigen receptor rearrangement, commonly shortened to PARR, evaluates whether lymphocytes share a dominant rearrangement pattern consistent with clonality. It can help in selected equivocal cases, especially when morphology and other tests do not settle whether a population is reactive or neoplastic. Clonality is not synonymous with malignancy, however, and technical false-negative or false-positive results can occur. The lymphoma consensus advises that PARR not replace phenotyping when the clinical question is B-cell versus T-cell lineage.
Plan the sample before collecting it
- Ask the laboratory which tube, transport medium, temperature, and delivery window are required for flow cytometry.
- Choose a representative node with the clinician; the easiest node to reach is not always the most informative.
- Tell the team about corticosteroids, chemotherapy, immune-modulating drugs, and recent vaccines before sampling.
- If tissue biopsy may be needed, coordinate fixation and fresh-sample allocation so one test does not consume material required by another.
- Request the cytology, pathology, flow report, and marker interpretation for the permanent record.
Questions that keep testing decision-focused
Owners can ask: What is established already? What uncertainty remains? Will lineage change the proposed treatment, the strength of a prognosis, or merely the name on the report? Is the current specimen adequate? Would tissue architecture add clinically important information? If an ancillary result conflicts with cell appearance, who will integrate the findings?
A reasonable answer may be to proceed with one test, several coordinated tests, or a narrower plan because the dog is unstable or the family would not act differently. Good diagnostics are proportional to the decision. New weakness, collapse, breathing difficulty, marked abdominal swelling, inability to eat or drink, or rapid deterioration warrants prompt veterinary assessment rather than waiting for a scheduled diagnostic appointment.